Cyclosporin A and Monoclonal Antibody Response in Rabbits
Author Information
Author(s): J.A. Ledermann, R.H.J. Begent, K.D. Bagshawe
Primary Institution: Cancer Research Campaign Laboratories, Department of Medical Oncology, Charing Cross Hospital
Hypothesis
Can cyclosporin A and ultracentrifugation of antibodies prevent the anti-antibody response in rabbits?
Conclusion
Cyclosporin A effectively prevents the formation of anti-antibodies to monoclonal antibodies in rabbits.
Supporting Evidence
- All 8 rabbits given cyclosporin A and ultracentrifuged antibody did not produce anti-mouse antibodies.
- 2 out of 8 rabbits given cyclosporin A and non-ultracentrifuged antibody produced anti-mouse antibodies.
- All rabbits not given cyclosporin A produced anti-mouse antibodies.
Takeaway
This study shows that a drug called cyclosporin A can help rabbits not make antibodies against a cancer treatment, which could help people get better treatment.
Methodology
Rabbits were given cyclosporin A and a monoclonal antibody, with some receiving ultracentrifuged antibody, to test for anti-antibody response.
Limitations
The study was conducted in rabbits, and results may not directly translate to humans.
Participant Demographics
New Zealand white rabbits, both male and female, weighing from 1.5 to 3.3 kg.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website